the latent infected cells from the uninfected cells; (2) even when antiretroviral drugs are able to completely suppress detectable HIV replication, these latent infected cells will remain and HIV can subsequently complete the viral replication cycle to produce more virus. Since proteosome inhibitors can activate lytic replication from latent infected cells, proteosome inhibitors may lead to therapies in which proteosome inhibitors are given together with highly active antiretroviral therapy in an effort to decrease or eliminate the reservoir of latent infected cells with hope of perhaps eventually curing a patient of HIV infection.

## Treatment of Human Viral Infections (Imatinib)

- Drs. Steven Zeichner and Vyjayanthi Krishnan (NCI).
- U.S. Provisional Application No. 60/ 588,015 filed 13 Jul 2004 (DHHS Reference No. E–281–2004/0–US–01).
- Licensing Contact: Sally Hu; 301/435– 5606; hus@mail.nih.gov.

This application describes the methods for treating or preventing a HIV infection by the administration of ablkinase inhibitor called imatinib and its derivatives. Several available agents can inhibit HIV replication by targeting one or another viral protein, such as the viral reverse transcriptase, protease, envelope fusion process, or integrase, or by targeting the interaction of a viral component with a host cell component, for example the host cell viral receptor or co-receptor. However, HIV can readily become resistant to these drugs, and new therapeutic approaches for HIV infection are needed. The studies described in the application show that the expression of many host cell genes changes in response to HIV replication, and show that targeting one of these changes with imatinib can inhibit viral replication. Thus targeting the host cell, and making the host cell less hospitable to the virus can inhibit viral replication. The application thus describes a new agent that inhibits viral replication by acting on the host cell, which may offer new approaches to therapy for HIV infection. These approaches may be less likely to engender rapid resistance in the virus to the therapy.

#### Treatment of Human Viral Infections (Farnesyl Transferase Inhibitors)

- Drs. Steven Zeichner and Vyjayanthi Krishnan (NCI).
- U.S. Provisional Application No. 60/ 587,771 filed 13 Jul 2004 (DHHS Reference No. E–282–2004/0–US–01).
- *Licensing Contact:* Sally Hu; 301/435–5606; *hus@mail.nih.gov.*

This application describes the methods for treating or preventing an HIV infection by the administration of farnesyl transferase inhibitors such as FTI277, L-744832, BMS214662, R115777 and SCH66336. It has been known that HIV, once it infects a cell, integrates into the cellular genome and can (1) rapidly undergo lytic infection, or (2) lay dormant for a period of time (latent infection). The existence of latent infected cells poses a great challenge to HIV therapy because (1) there are no good existing means that can separate the latent infected cells from the uninfected cells; (2) even when antiretroviral drugs are able to completely suppress detectable HIV replication, these latent infected cells will remain and HIV can subsequently complete the viral replication cycle to produce more virus. Since farnesyl transferase inhibitors can activate lytic replication from latent infected cells by modulating membrane-bound Ras-Rho levels, farnesyl transferase inhibitors may lead to therapies in which farnesyl transferase inhibitor is given together with highly active antiretroviral therapy in an effort to decrease or eliminate the reservoir of latent infected cells with hope of perhaps eventually curing a patient of HIV infection.

Dated: May 17, 2005.

#### Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 05–10316 Filed 5–23–05; 8:45 am]

BILLING CODE 4140-01-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. *Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel Review of Research Projects (Cooperative Agreements) U01s.

Date: May 27, 2005.

*Time:* 9 a.m. to 11 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Valerie L. Prenger, PhD, Health Scientist Administrator, Review Branch, Room 7214, Division of Extramural Affairs, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, MSC 7924, Bethesda, MD 20892–7924, (301) 435–0270, prengerv@nhlbi.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: May 16, 2005.

LaVerne Y. Stringfield, Director, Office of Federal Advisory

*Committee Policy.* [FR Doc. 05–10327 Filed 5–23–05; 8:45 am] BILLING CODE 4140–01–M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## National Institutes of Health

### National Institute of Dental and Craniofacial Research; Notice of Meeting

Notice is hereby given of a Conference on Research Training Initiatives, sponsored by the National Institute of Dental and Craniofacial Research (NIDCR).

The conference will be open to the public as indicated below, with attendance limited to space available. This meeting will also be made available by video cast at *http://videocast.nih.gov/.* 

*Conference Name:* Research Training Initiatives.

*Date:* June 9, 2005.

*Open:* 8:30 a.m. to 5 p.m.

Agenda: The conference will focus on a variety of issues relating to research training. A significant portion of the meeting will be devoted to discussion of training of both clinician scientists and basic scientists, from building a pipeline, through undergraduate, graduate and postgraduate research training culminating in bridging to scientific independence. Additional presentations and discussion will focus on models for successful programs at various educational and career development stages, definition of what constitutes success, the role of mentoring, academic environment, K–12 science education and related topics.

Speakers and plenary discussion panel members include representatives from the NIH, the National Academics of Science, the National Science Foundation and the Howard Hughes Medical Institute.

*Place:* National Institutes of Health, Natcher Building (Building 45), Conference Rm. 1–2, 4500 Center Drive, Bethesda, MD 20892.

Public Comment: Individuals who wish to provide public comment (oral or written) should contact the Acting Deputy Director, NIDCR, Dr. Henning Birkedal Hansen, by telephone at (301) 496–9469 or e-mail at Henning.Birkedal-Hansen@nih.gov no later than May 25, 2005.

*Contact Person:* Henning Birkedal-Hansen, Ph.D., Acting Deputy Director, National Institute of Dental and Craniofacial Research, 31 Center Drive, Room 2C39, Bethesda, MD 20892, (301) 496–9469.

Information is also available on the Institute's home page: *http:// www.nidcr.nih.gov/about*, where an agenda and any additional information for the meeting will be posted when available.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify Ms. Rita Lehr at (301) 496–9469 prior to the meeting.

Dated: May 18, 2005.

## Henning Birkedal-Hansen,

Acting Deputy Director, National Institute of Dental and Craniofacial Research. [FR Doc. 05–10317 Filed 5–23–05; 8:45 am] BILLING CODE 4140–01–M

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

## National Institute of Dental & Craniofacial Research; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel, 05–52, Review R21s.

*Date:* June 20, 2005. *Time:* 1:45 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: H. George Hausch, PhD, Acting Director, 45 Center Drive, Natcher Building, Rm. 4AN44F, National Institutes of Health, Bethesda, MD 20892, (301) 594–2904, george\_hausch@nih.gov.

*Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel, 05–78, Review R13.

Date: June 23, 2005.

*Time:* 2 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Mary Kelly, Scientific Review Specialist, National Institute of Dental & Craniofacial Res., 45 Center Drive, Natcher Bldg., RM 4AN38J, Bethesda, MD 20892–6402, (301) 594–4809, mary kelly@nih.gov.

Name of Committee: National Institute of Dental and Craniofacial Research Special

Emphasis Panel, 05–76, Review R13. Date: June 28, 2005.

*Time:* 2 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda,

MD 20892, (Telephone Conference Call). Contact Person: Mary Kelly, Scientific

Review Specialist, National Institute of Dental & Craniofacial Res., 45 Center Drive, Natcher Bldg., RM 4AN38J, Bethesda, MD 20892–6402, (301) 594–4809, mary kelly@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: May 16, 2005.

## LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 05–10318 Filed 5–23–05; 8:45 am] BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

# National Institutes of Health

### National Institute of Dental & Craniofacial Research; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Dental and Craniofacial Research.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Dental & Craniofacial Research, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Board of Scientific Counselors, National Institute of Dental and Craniofacial Research, Review of the Craniofacial & Skeletal Diseases Branch, NIDCR.

Date: May 25-27, 2005.

*Closed:* May 25, 2005, 7 p.m. to 8:30 p.m. *Agenda:* To review and evaluate personal qualifications and performance, and competence of individual investigators.

*Place:* National Institutes of Health, Building 30, 30 Convent Drive, Conference

Room 117, Bethesda, MD 20892.

*Open:* May 26, 2005, 8:30 a.m. to 11:40 a.m.

Agenda: Investigator presentations. Place: National Institutes of Health, Building 30, 30 Convent Drive, Conference Room 117, Bethesda, MD 20892.

*Closed:* May 26, 2005, 11:40 a.m. to 1 p.m. *Agenda:* To review and evaluate personal qualifications and performance, and

competence of individual investigators. *Place:* National Institutes of Health,

Building 30, 30 Convent Drive, Conference Room 117, Bethesda, MD 20892.

Open: May 26, 2005, 1 p..m. to 6 p.m. Agenda: Investigator presentations, Lab Tour, Poster Presentation.

Place: National Institutes of Health, Building 30, 30 Convent Drive, Conference Room 117, Bethesda, MD 20892. Closed: May 27, 2005, 8:30 a.m. to 3 p.m.